Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - dobutamine hydrochloride - solution for infusion - 5mg/1ml

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - dobutamine hydrochloride - solution for infusion - 12.5mg/1ml

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine in 5% dextrose injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine in 5% dextrose injection, usp is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

hainan poly pharm. co., ltd. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

hospira nz ltd - dobutamine hydrochloride 14.01 mg/ml equivalent to 12.5 mg/ml dobutamine - solution for injection - 12.5 mg/ml - active: dobutamine hydrochloride 14.01 mg/ml equivalent to 12.5 mg/ml dobutamine excipient: sodium metabisulfite water for injection

Kanada - anglų - Health Canada

sanofi canada, inc. - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - sympathomimetic (adrenergic) agents

Kanada - anglų - Health Canada

novopharm limited - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, solution - excipient ingredients: sodium metabisulfite; water for injections - dobutamine hydrochloride injection is indicated in adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.

Airija - anglų - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

Airija - anglų - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - concentrate for soln for inf - 50 mg/ml